An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL: Anifrolumab
DRUG: Placebo

Sponsor

AstraZeneca